<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36315">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02633800</url>
  </required_header>
  <id_info>
    <org_study_id>U31287-A-U203</org_study_id>
    <nct_id>NCT02633800</nct_id>
  </id_info>
  <brief_title>A Clinical Trial Using Patritumab or Placebo in Combination With Cetuximab and a Platinum Agent for Patients With Squamous Cell Cancer of the Head and Neck</brief_title>
  <official_title>RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PHASE 2 STUDY OF PATRITUMAB (U3-1287) IN COMBINATION WITH CETUXIMAB PLUS PLATINUM-BASED THERAPY IN FIRST LINE SETTING IN SUBJECTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Daiichi Sankyo Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 'randomized study' which means you may receive a substance that looks like the
      active medication but is not (called placebo). The study will test an investigational study
      drug called patritumab/placebo. Patritumab may work when combined with other medications
      that are approved for the treatment of head and neck cancer. They are called cetuximab,
      cisplatin or carboplatin.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>from Day 0 to end of active study, approximately 22 months</time_frame>
    <description>first objective documentation of radiographic disease progression (per RECIST v1.1) or death due to any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>from Day 0 to end of study follow-up, approximately 25 months</time_frame>
    <description>Overall survival (OS) is defined from the date of randomization to death to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>from Day 0 to end of active study, approximately 22 months</time_frame>
    <description>Proportion of subjects with the best ORR of CR or PR regardless of whether it is confirmed or unconfirmed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Neoplasms by Site</condition>
  <condition>Head and Neck Neoplasms</condition>
  <condition>Squamous Cell Cancer of the Head and Neck</condition>
  <arm_group>
    <arm_group_label>Patritumab/cetuximab/cisplatin or carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patritumab initial loading dose is 18 mg/kg IV over 60 minutes followed bya maintenance dose of 9 mg/kg IV over 60 minutes (± 10 minutes) every three weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo/cetuximab/cisplatin or carboplatin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>patritumab</intervention_name>
    <description>Patritumab initial loading dose is 18 mg/kg IV over 60 minutes followed bya maintenance dose of 9 mg/kg IV over 60 minutes (± 10 minutes) every three weeks</description>
    <arm_group_label>Patritumab/cetuximab/cisplatin or carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>400mg/mg/m2 iv loading dose, followed by 250 mg/m2 weekly</description>
    <arm_group_label>Patritumab/cetuximab/cisplatin or carboplatin</arm_group_label>
    <arm_group_label>placebo/cetuximab/cisplatin or carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin or carboplatin</intervention_name>
    <description>Cisplatin at 100 mg/m2 IV infused over 1 hour, every three weeks up to a maximum of 6 cycles or Carboplatin: at AUC 5 IV bolus over 30 to 60 minutes, every 3 weeks for a maximum of 6 cycles</description>
    <arm_group_label>Patritumab/cetuximab/cisplatin or carboplatin</arm_group_label>
    <arm_group_label>placebo/cetuximab/cisplatin or carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo to match patritumab</description>
    <arm_group_label>placebo/cetuximab/cisplatin or carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects ≥18 years old

          -  Histologically confirmed recurrent disease or metastatic SCCHN tumor and/or from its
             lymph nodal metastases originating from the oral cavity, oropharynx, hypopharynx, and
             larynx

          -  Must have or be willing to provide tumor tissue for testing

          -  Measurable disease per Response Evaluation Criteria in Solid Tumor (RECIST) Version
             1.1

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Adequate hematological function

          -  Adequate renal function

          -  Adequate hepatic function

          -  Agreement to use effective contraception while on the study and for 6-months after
             the end of the study

          -  Provided written informed consent(s)

        Exclusion Criteria:

          -  Left ventricular ejection fraction (LVEF) &lt;50%

          -  Prior EGFR targeted regimen

          -  Prior anti-HER3 therapy

          -  Prior chemotherapy for recurrent/metastatic disease

          -  Anti-cancer therapy between biopsy and submission of sample

          -  History of other malignancies, except adequately treated non-melanoma skin cancer,
             curatively treated in-situ disease, or other solid tumors curatively treated with no
             evidence of disease for ≥ 2 years

          -  Known history of brain metastases or active brain metastases

          -  Uncontrolled hypertension

          -  Clinically significant electrocardiograph (ECG) findings

          -  Myocardial infarction within 1 year before enrollment, symptomatic congestive heart
             failure, unstable angina, or arrhythmia requiring medication

          -  Platinum-containing drug therapy with radiotherapy less than 6 months before study
             drug treatment

          -  Therapeutic or palliative radiation therapy or major surgery within 4 weeks before
             study drug treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Harrington, Professor, Physician</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Norman Neville, MD</last_name>
    <phone>49 8092 336766</phone>
    <email>Norman.Neville@covance.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <state>Cedex</state>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kecskemet</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Nyíregyháza</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Konin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Surrey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 23, 2016</lastchanged_date>
  <firstreceived_date>December 15, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>squamous cell cancer of the head and neck</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Neoplasms by Site</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
